<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Rheumatol J</journal-id><journal-id journal-id-type="iso-abbrev">Open Rheumatol J</journal-id><journal-id journal-id-type="publisher-id">TORJ</journal-id><journal-title-group><journal-title>The Open Rheumatology Journal</journal-title></journal-title-group><issn pub-type="epub">1874-3129</issn><publisher><publisher-name>Bentham Open</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22629288</article-id><article-id pub-id-type="pmc">3358714</article-id><article-id pub-id-type="publisher-id">TORJ-6-44</article-id><article-id pub-id-type="doi">10.2174/1874312901206010044</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Adverse Events in Patients with Blood Loss: A Pooled Analysis of 51 Clinical Studies from the Celecoxib Clinical Trial Database</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sands</surname><given-names>GH</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Shell</surname><given-names>B</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name></contrib></contrib-group><aff>Pfizer Inc, New York, NY, USA</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at the Pfizer Inc., 235 East 42nd Street, New York, NY, USA; Tel: +1 212 733 6358; Fax: +1 212 309 4481; E-mail: <email xlink:href="george.sands@pfizer.com">george.sands@pfizer.com</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>5</month><year>2012</year></pub-date><pub-date pub-type="collection"><year>2012</year></pub-date><volume>6</volume><fpage>44</fpage><lpage>49</lpage><history><date date-type="received"><day>19</day><month>1</month><year>2012</year></date><date date-type="rev-recd"><day>8</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; Sands <italic>et al</italic>.; Licensee <italic>Bentham Open</italic>.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Sands</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</uri>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of gastrointestinal (GI) toxicity, including occult blood loss and the development of clinically significant anemia. The aim of this study was to investigate the clinical importance of clinically significant anemia/blood loss.</p></sec><sec><title>Methods:</title><p>Pooled analysis of 51 blinded, controlled clinical studies &#x02265;4 weeks duration from the celecoxib clinical trial database, comparing celecoxib with NSAIDs or placebo. The adverse event (AE) profile in patients with clinically significant anemia/blood loss (defined as decreases in hemoglobin &#x02265;2 g/dL and/or hematocrit by &#x02265;10% from baseline) was compared with the AE profile in patients without blood loss. Events that occurred in &#x0003c;0.5% of patients were excluded from any comparisons. A threefold difference between groups was defined arbitrarily as being markedly higher.</p></sec><sec><title>Results:</title><p>Overall 932/51,048 patients experienced clinically significant anemia/blood loss. Baseline demographics were similar in both groups. The incidence of AEs was markedly higher in patients who experienced clinically significant anemia/blood loss than those who did not; the majority of these differences were for GI AEs or their likely sequelae. The incidence of the following non-GI related AEs was also markedly higher in patients with blood loss: coronary artery disease (1.2% <italic>vs </italic>0.3%), myocardial infarction (0.6% <italic>vs </italic>0.2%), and pneumonia (1.7% <italic>vs </italic>0.4%). Withdrawals due to AEs were more common among patients who experienced blood loss (16.7% <italic>vs </italic>10.4%).</p></sec><sec><title>Conclusions:</title><p>Clinically significant anemia/blood loss may have clinically important adverse consequences beyond the sequelae previously known to be associated with NSAID-related GI effects.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Blood loss</kwd><kwd>NSAIDs</kwd><kwd>GI.</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective anti-inflammatory, antipyretic, and analgesic agents and are among the most widely prescribed drugs worldwide [<xref ref-type="bibr" rid="R1">1</xref>]. However, despite their accepted efficacy, it is well recognized that use of NSAIDs is associated with an increased risk of gastrointestinal (GI) damage, including overt bleeding, ulceration, occult blood loss, and the development of clinically significant anemia or blood loss [<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3"> 3</xref>].</p><p>Recent evidence suggests some patients with mildly low or low-normal hemoglobin levels may have an increased risk of frailty, poor functional outcomes, hospitalization, and mortality [<xref ref-type="bibr" rid="R4">4</xref>-<xref ref-type="bibr" rid="R7">7</xref>]. In the recent Celecoxib versus Omeprazole and Diclofenac in Patients with Osteoarthritis and Rheumatoid Arthritis (CONDOR) randomized clinical trial [<xref ref-type="bibr" rid="R8">8</xref>] comparing the risk of GI events through the entire GI tract, clinically significant anemia or blood loss (predefined as a <italic>decrease in hemoglobin &#x02265;2 g/dL and/or hematocrit &#x02265;10% points from baseline</italic>) was an important component of the composite primary GI endpoint [<xref ref-type="bibr" rid="R8">8</xref>]. Although blood loss is common in patients taking NSAIDs, few studies have been performed to determine the exact burden and clinical impact of this problem in patients taking NSAIDs or aspirin, or to determine whether blood loss is associated with other more clinically apparent adverse events (AEs). The objective of this analysis of pooled data from the celecoxib clinical trial database, including both patients treated with NSAIDs and placebo, was to investigate whether there is a clinically important difference in the AE profile of patients with clinically significant anemia or blood loss (predefined as a <italic>decrease in hemoglobin &#x02265;2 g/dL and/or hematocrit &#x02265;10% points from baseline</italic>) compared with patients without such blood loss, regardless of treatment.</p></sec><sec><title>MATERIALS AND METHODOLOGY</title><sec><title>Study Design and Selection</title><p>This was a retrospective, pooled analysis of 51 blinded, controlled clinical studies comparing celecoxib, a cyclooxygenase (COX)-2 selective NSAID, with other COX-2 selective and nonselective NSAIDs (nsNSAIDs) or placebo. To be eligible for inclusion, all clinical study reports (from Pfizer&#x02019;s Celecoxib Clinical Trial Database) must have been finalized by October 1, 2007; only randomized, double-blind controlled clinical trials with at least one celecoxib and one comparator (active or placebo) group, of a planned duration of daily treatment &#x02265;4 weeks, were included. All open-label extensions, crossover trials, and healthy volunteer studies were excluded. With these criteria applied, the resulting pooled dataset represents both male and female patients with osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), chronic low back pain, Alzheimer disease, and/or spontaneous adenomatous colorectal polyps.</p></sec><sec><title>Data Collection</title><p>The primary end point was blood loss status (Y/N) defined as &#x0201c;Yes&#x0201d; if a patient had a <italic>&#x02265;2 g/dL hemoglobin drop and/or &#x02265;10% hematocrit drop from baseline.</italic> This definition is consistent with the definition of clinically significant anemia or blood loss used (as a component of the composite primary GI end point) in both the CONDOR and Gastrointestinal Randomized Event and Safety Open-label NSAID Study (GI-REASONS) randomized clinical trials [<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9"> 9</xref>]; the GI-REASONS study uses a prospectively randomized open-label blinded end point (PROBE) design (neither the CONDOR or GI-REASONS trials were included in this analysis, as they did not meet the clinical study report finalization date criterion).</p><p>To determine whether there were any clinically important consequences in patients with blood loss as defined above, the AE profile in patients with the blood loss status &#x0201c;Yes&#x0201d; was compared with the AE profile in patients without such blood loss. For the primary analysis, an AE was considered to be associated with blood loss if it occurred at any time during the time window from the last laboratory day normal hemoglobin/hematocrit values were recorded (before the first hemoglobin/hematocrit decrease), to the day hemoglobin/hematocrit values returned to normal <italic><bold>or </bold></italic>30 days after the hemoglobin/hematocrit decrease, whichever occurred first (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>).</p></sec><sec><title>Statistical Analysis</title><p>The pooled analysis was performed on the safety population (all patients who were randomized in any of the included 51 clinical trials who took at least one dose of study medication and who had at least one safety assessment). Summary statistics were used to compare AE profiles (preferred AE terms based on Medical Dictionary for Regulatory Activities, MedDRA 11.0) in patients who had clinically significant blood loss (&#x0201c;Yes&#x0201d; for the primary end point) versus patients who did not (&#x0201c;No&#x0201d; for the primary end point). When comparing the percentage of patients with specific AEs between the groups, a threefold difference was defined arbitrarily as being &#x0201c;markedly higher&#x0201d;; any AE that occurred for &#x0003c;0.5% of patients in both groups was excluded from treatment comparisons.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Included Studies</title><p>A total of 51 double-blind, randomized clinical trials met the criteria for inclusion and were pooled for this retrospective analysis (please see list of clinical trials, including details on study duration and comparator treatments in Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). Study duration ranged from 4 weeks to 3 years. One study was event-driven, and thus patients in this study were exposed to study medication for different durations (median duration of 6-9 months), rather than for a protocol-defined time period.</p></sec></sec><sec><title>PATIENTS</title><p>Generally, the majority of patients with clinically significant blood loss were approximately 1-year older than those without blood loss (mean age, 61 years <italic>vs</italic> 60 years, respectively; Table <bold><xref ref-type="table" rid="T2">2</xref></bold>). Overall 932/51,048 (1.83%) patients in the 51 studies described above experienced clinically significant anemia or blood loss (predefined by a <italic>decrease in hemoglobin &#x02265;2 g/dL and/or hematocrit &#x02265;10% from baseline</italic>). The majority of patients in both groups had follow-up for &#x0003e;6&#x000a0;months, and baseline demographics were similar when patients with clinically significant blood loss were compared with those without (Table <bold><xref ref-type="table" rid="T2">2</xref></bold>) such blood loss.</p><sec><title>End Points</title><p>In general, patients with clinically significant blood loss had a higher incidence of AEs than those who did not (66% and 58%, respectively; Table <bold><xref ref-type="table" rid="T3">3</xref></bold>). The majority of the difference between groups could be accounted for by AEs representing GI disorders or their likely sequelae. The specific AEs of this type that were markedly increased (defined as greater than threefold difference) for patients with clinically significant blood loss versus those without it were: gastric ulcer (1.5% <italic>vs</italic> 0.2%, respectively); GI hemorrhage (0.8% <italic>vs</italic> &#x0003c;0.1%); esophageal ulcer (0.5% <italic>vs</italic> &#x0003c;0.1%); melena (1.3% <italic>vs</italic> 0.1%); anemia (8.8% <italic>vs</italic> 0.6%); increase in blood creatinine (1.7% <italic>vs</italic> 0.4%); decrease in hemoglobin (8.9% <italic>vs</italic> 0.2%); decrease in hematocrit (10.4% <italic>vs</italic> 0.5%); decrease in red blood cell count (0.8% <italic>vs</italic> &#x0003c;0.1%); and hematochezia (1.0% <italic>vs</italic> 0.3%).</p><p>However, the incidence of the following <italic>non-GI related AEs</italic> was also markedly higher in patients with clinically significant blood loss compared with patients without such blood loss: coronary artery disease (1.2% <italic>vs</italic> 0.3%, respectively), myocardial infarction (0.6% <italic>vs</italic> 0.2%), and pneumonia (1.7% <italic>vs</italic> 0.4%).</p><p>Withdrawals due to AEs were more common among patients who had clinically significant blood loss (17%) than among those who did not (10%) have such blood loss.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The findings of this retrospective pooled analysis support the hypothesis that a <italic>decrease in hemoglobin &#x02265;2 g/dL and/or hematocrit &#x02265;10% points from baseline </italic>represents a clinically relevant event. As might be expected, hematologic observations of this type may be associated with pathophysiologic processes that result in either overt bleeding (e.g. GI hemorrhage and melena) or lesions that may reasonably be expected to account for bleeding that cannot be observed directly (e.g. gastric and esophageal ulcers). However, pathophysiologic states resulting from such blood loss, for example a reduction in oxygen-carrying capacity or a compromised immune system, may explain the increased incidence of particular non-GI AEs observed in patients with blood loss (e.g. myocardial infarction, coronary artery disease, and pneumonia). As these kinds of events are relatively rare in clinical trial populations, it is not clear whether the inability to detect other non-GI events of related etiology in this current analysis was a result of underpowering due to limited sample size or due to more mechanistic effects.</p><p>The goal of this analysis was to better understand the clinical implications of a <italic>decrease in hemoglobin &#x02265;2 g/dL and/or hematocrit &#x02265;10% points from baseline</italic> over time. Both the CONDOR [<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9"> 9</xref>] and GI-REASONS [<xref ref-type="bibr" rid="R9">9</xref>] trials included this measure of clinically significant blood loss as a component of the predefined composite primary GI end point for &#x0201c;Clinically Significant Upper and Lower GI Events.&#x0201d; In contrast to the current analysis, the end point, in these two clinical trials, was adjudicated by an independent expert blinded panel to be of confirmed or likely GI source. We now know the majority of the primary end point events in CONDOR were adjudicated as meeting this prespecified definition of clinically significant blood loss rather than the more traditional end point for evaluation of GI effects for NSAIDs&#x02014;GI perforations, ulcers, or overt bleeds (PUBs), or &#x0201c;ulcer complications&#x0201d; [<xref ref-type="bibr" rid="R8">8</xref>]. Thus, the results of this current respective analysis of data from 51&#x000a0;clinical studies may help to establish the clinical importance of blood loss events that are not readily identifiable as PUBs.</p><p>The findings of the CONDOR trial [<xref ref-type="bibr" rid="R8">8</xref>] and the previous Celecoxib Long-term Arthritis Safety Study (CLASS) [<xref ref-type="bibr" rid="R10">10</xref>] suggest clinically significant blood loss, as defined in the current analysis and the CONDOR trial, is a consequence of the effects of NSAIDs on GI physiology. In both CONDOR and CLASS, decreases in hemoglobin &#x02265;2 g/dL occurred similarly over time, despite differences in trial design, and were prevalent in these patients treated with NSAIDs [<xref ref-type="bibr" rid="R11">11</xref>]. In another recent study of 892 randomized participants with chronic knee pain, who were treated with either non-prescription doses of ibuprofen and acetaminophen or two different non-prescription dose combinations of ibuprofen/acetaminophen, up to approximately 18% of all participants had decreases of <italic>hemoglobin &#x02265;2 g/dL in the various treatment groups, supporting the clinical relevance of this safety measure</italic> [<xref ref-type="bibr" rid="R12">12</xref>]. Of these three&#x000a0;trials for which published data are available, CLASS and CONDOR had decreases in hemoglobin &#x02265;2 g/dL prespecified for analysis; in the CONDOR trial (but not the CLASS trial) these decreases were also adjudicated for association with GI sources.</p><p>Strand <italic>et al.,</italic> analyzed 14 randomized clinical trials from the celecoxib database, including more than 14,000 arthritis patients, and discovered treatment in patients with decreases in hemoglobin &#x02265;2 g/dL was associated with no improvement in physical function, contrasting to those patients with no decreases in hemoglobin. Following treatment, the latter group of patients demonstrated improvements in physical functioning, as assessed by the Medical Outcomes Study Short Form with 36 questions (SF-36) [<xref ref-type="bibr" rid="R13">13</xref>].</p></sec><sec><title>STRENGTHS/LIMITATIONS</title><p>One of the strengths of this analysis was the inclusion of more than 51,000 patients with active disease&#x02014;OA, RA, or AS&#x02014;giving a robust sample size. A second strength, was the use of the prespecified definition of clinically significant anemia or blood loss (previously used in both the CONDOR and GI-REASONS randomized clinical trials). However, we should be cautious when interpreting these findings as even in this analysis population of more than 51,000 patients, some of the specific AEs examined occurred in too few patients to provide the most robust information. Furthermore, analysis of trials solely from the celecoxib trial database might exclude relevant trials conducted elsewhere, and while many of the randomized controlled trials included in this pooled analysis had a similar study structure, they were not identical, which could potentially have introduced bias.</p></sec><sec sec-type="conclusion"><title>CONCLUSION</title><p>Clinically significant anemia or blood loss, defined as <italic>decreases in hemoglobin &#x02265;2 g/dL and/or hematocrit by &#x02265;10% from baseline</italic>, may have clinically important adverse consequences beyond the sequelae previously known to be associated with NSAID-related GI effects. The discovery of gastric and esophageal ulcers in the group of patients with a markedly higher incidence of clinically significant blood loss suggests possible occult GI bleeding from this source. The markedly increased incidence for some <italic>non-GI related AE</italic> terms suggests clinically significant blood loss may be especially important in those patients needing all of their oxygen-carrying capacity. Further studies are required to better understand the clinical importance of clinically significant anemia or blood loss.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS AND FUNDING</title><p>The study was sponsored by Pfizer Inc. All authors were full-time employees at the time the manuscript was written. Editorial support was provided by L. Prevost, of PAREXEL, and was funded by Pfizer Inc.</p></ack><sec><title>TRIAL REGISTRATION</title><p>Current controlled trials N499602012, N499602020, N499602021, N499602022, N499602023, I499602041, I499 602042, N499602047, N499602054, N499602060, N49960 2062, N499602071, N499602087, I499602096, N4996020 35/102, I499602105, I499602106, I499602107, N4996021 18, N499602149, N499602152, N499602181, J490102216, 635IFL0508002, 635IFL0508003, A3191006, A3191025, A3191051, A3191052, A3191053, A3191062, A3191063, A3191069, A3191082, A3191152, COXA0508261, F49980 2137, N490102193, COXA0503243, COXA0503247, J4901 02217, COXA0508244, COXA0508245, COXA0508269, A3191174, IQ59702001, EQ59802002, NQ59802005, NQ40002011, EQ40002018, and IQ49902005.</p></sec><sec><title>CONFLICT OF INTEREST</title><p>GEORGE H. SANDS &#x02013; Pfizer Inc. full-time employee and shareholder.</p><p>BRITON SHELL &#x02013; Pfizer Inc. full-time employee and shareholder.</p><p>RICHARD ZHANG &#x02013; Pfizer Inc. full-time employee and shareholder.</p></sec><sec><title>AUTHOR&#x02019;S CONTRIBUTIONS</title><p>GEORGE H. SANDS &#x02013; design of study, analysis and interpretation of the data, critical revision/drafting of the manuscript, final approval to submit.</p><p>BRITON SHELL &#x02013; design of study, analysis and interpretation of the data, critical revision/drafting of the manuscript, final approval to submit.</p><p>RICHARD ZHANG &#x02013; statistical analysis and interpretation, critical revision/drafting of the manuscript, final approval to submit.</p></sec><glossary><title>ABBREVIATIONS</title><def-list><def-item><term id="A1">AE</term><def><p>&#x02003;=&#x02003;Adverse event </p></def></def-item><def-item><term id="A2">AS</term><def><p>&#x02003;=&#x02003;Ankylosing spondylitis </p></def></def-item><def-item><term id="A3">CLASS Study</term><def><p>&#x02003;=&#x02003;Celecoxib Long-term Arthritis Safety</p></def></def-item><def-item><term id="A4">BID</term><def><p>&#x02003;=&#x02003;Twice daily </p></def></def-item><def-item><term id="A5">CONDOR</term><def><p>&#x02003;=&#x02003;Celecoxib versus Omeprazole and Diclofenac in Patients with Osteoarthritis and Rheumatoid Arthritis </p></def></def-item><def-item><term id="A6">COX</term><def><p>&#x02003;=&#x02003;Cyclooxygenase </p></def></def-item><def-item><term id="A7">GI</term><def><p>&#x02003;=&#x02003;Gastrointestinal </p></def></def-item><def-item><term id="A8">GI-REASONS</term><def><p>&#x02003;=&#x02003;Gastrointestinal Randomized Event and Safety Open-label NSAID Study </p></def></def-item><def-item><term id="A9">MedDRA</term><def><p>&#x02003;=&#x02003;The Medical Dictionary for Regulatory Activities </p></def></def-item><def-item><term id="A10">NSAIDs</term><def><p>&#x02003;=&#x02003;Nonsteroidal anti-inflammatory drugs </p></def></def-item><def-item><term id="A11">OA</term><def><p>&#x02003;=&#x02003;Osteoarthritis </p></def></def-item><def-item><term id="A12">PROBE</term><def><p>&#x02003;=&#x02003;Prospectively randomized open-label blinded end point </p></def></def-item><def-item><term id="A13">PUBs</term><def><p>&#x02003;=&#x02003;GI perforations, ulcers, or overt bleeds </p></def></def-item><def-item><term id="A14">QD</term><def><p>&#x02003;=&#x02003;Once daily </p></def></def-item><def-item><term id="A15">RA</term><def><p>&#x02003;=&#x02003;Rheumatoid arthritis </p></def></def-item><def-item><term id="A16">SF-36</term><def><p>&#x02003;=&#x02003;Short Form with 36 questions </p></def></def-item><def-item><term id="A17">TID</term><def><p>&#x02003;=&#x02003;Three times daily </p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Scheiman</surname><given-names>JM</given-names></name><name><surname>Hindley</surname><given-names>CE</given-names></name></person-group><article-title>Strategies to optimize treatment with
NSAIDs in patients at risk for gastrointestinal and cardiovascular
adverse events</article-title><source>Clin Ther</source><year>2010</year><volume>32</volume><fpage>667</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">20435236</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Allison</surname><given-names>MC</given-names></name><name><surname>Howatson</surname><given-names>AG</given-names></name><name><surname>Torrance</surname><given-names>CJ</given-names></name><name><surname>Lee</surname><given-names>FD</given-names></name><name><surname>Russell</surname><given-names>RI</given-names></name></person-group><article-title>
Gastrointestinal damage associated with the use of nonsteroidal
antiinflammatory drugs</article-title><source>N Engl J Med</source><year>1992</year><volume>327</volume><fpage>749</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">1501650</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Lanas</surname><given-names>A</given-names></name><name><surname>Sopena</surname><given-names>F</given-names></name></person-group><article-title>Nonsteroidal anti-inflammatory drugs and
lower gastrointestinal complications</article-title><source>Gastroenterol Clin North Am
</source><year>2009</year><volume>38</volume><fpage>333</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">19446262</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Eisenstaedt</surname><given-names>R</given-names></name><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Woodman</surname><given-names>RC</given-names></name></person-group><article-title>Anemia in the elderly:
current understanding and emerging concepts</article-title><source>Blood Rev</source><year>2006</year><volume>20</volume><fpage>
213</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">16472893</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Penninx</surname><given-names>BW</given-names></name><name><surname>Pluijm</surname><given-names>SMF</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name><etal/></person-group><article-title>Late-life anemia is
associated with increased risk of recurrent falls</article-title><source>J Am Geriatr Soc
</source><year>2005</year><volume>53</volume><fpage>2106</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">16398894</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Penninx</surname><given-names>BW</given-names></name><name><surname>Pahor</surname><given-names>M</given-names></name><name><surname>Woodman</surname><given-names>RC</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name></person-group><article-title>Anemia in old
age is associated with increased mortality and hospitalization</article-title><source>J
Gerontol A Biol Sci Med Sci</source><year>2006</year><volume>61A</volume><fpage>474</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16720744</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Chaves</surname><given-names>PH</given-names></name><name><surname>Xue</surname><given-names>QL</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Volpato</surname><given-names>S</given-names></name><name><surname>Fried</surname><given-names>
LP</given-names></name></person-group><article-title>What constitutes normal hemoglobin concentration in
community-dwelling disabled older women?</article-title><source>J Am Geriatr Soc
</source><year>2004</year><volume>52</volume><fpage>1811</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15507056</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Chan</surname><given-names>FK</given-names></name><name><surname>Lanas</surname><given-names>A</given-names></name><name><surname>Scheiman</surname><given-names>J</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Goldstein</surname><given-names>
JL</given-names></name></person-group><article-title>Celecoxib versus omeprazole and diclofenac in patients with
osteoarthritis and rheumatoid arthritis (CONDOR): a randomised
trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>173</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20638563</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Chan</surname><given-names>FK</given-names></name><name><surname>Cryer</surname><given-names>B</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><etal/></person-group><article-title>A novel composite endpoint
to evaluate the gastrointestinal (GI) effects of nonsteroidal
antiinflammatory drugs through the entire GI tract</article-title><source>J Rheumatol
</source><year>2010</year><volume>37</volume><fpage>167</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">19884267</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Silverstein</surname><given-names>FE</given-names></name><name><surname>Faich</surname><given-names>G</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Gastrointestinal
toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for
osteoarthritis and rheumatoid arthritis: the CLASS study: a
randomized controlled trial. Celecoxib Long-term Arthritis Safety
Study</article-title><source> JAMA</source><year>2000</year><volume>284</volume><fpage>1247</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">10979111</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Goldstein</surname><given-names>JL</given-names></name><name><surname>Chan</surname><given-names>FK</given-names></name><name><surname>Lanas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Haemoglobin decreases in
NSAID users over time: an analysis of two large outcome trials</article-title><source>
Aliment Pharmacol Ther</source><year>2011</year><volume>34</volume><fpage>808</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">21810115</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Doherty</surname><given-names>M</given-names></name><name><surname>Hawkey</surname><given-names>C</given-names></name><name><surname>Goulder</surname><given-names>M</given-names></name><etal/></person-group><article-title>A randomised controlled
trial of ibuprofen, paracetamol or a combination tablet of
ibuprofen/paracetamol in community-derived people with knee
pain</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><fpage>1534</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">21804100</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname> Strand</surname><given-names>V</given-names></name><name><surname>Cryer</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Effect of blood loss on physical
function in arthritis patients: a pooled analysis</article-title><source>Health Outcomes
Res Med</source><year>2011</year><volume>2</volume><fpage>e27</fpage><lpage>e38</lpage></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. (1)</label><caption><p>Adverse events associated with blood loss.</p></caption><graphic xlink:href="TORJ-6-44_F1"/></fig><table-wrap id="T1" position="float"><label>Table 1.</label><caption><p>Clinical Studies Included in the Pooled Analysis</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th style="background-color:#D9D9D9;" rowspan="1" colspan="1"/><th style="background-color:#D9D9D9;" rowspan="1" colspan="1">Duration of Treatment</th><th style="background-color:#D9D9D9;" rowspan="1" colspan="1">Treatment Groups</th></tr></thead><tbody><tr><td colspan="3" rowspan="1"><bold>Osteoarthritis and/or Rheumatoid
Arthritis</bold></td></tr><tr><td rowspan="1" colspan="1">N49-96-02-012</td><td rowspan="1" colspan="1">4 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 40 mg BID,
celecoxib 200 mg BID, celecoxib 400 mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-020</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 50 mg BID,
celecoxib 100 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-021</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 50 mg BID,
celecoxib 100 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-022</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 100 mg BID,
celecoxib 200 mg BID, celecoxib 400 mg BID, naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-023</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 100 mg BID,
celecoxib 200 mg BID, celecoxib 400 mg BID, naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">I49-96-02-041</td><td rowspan="1" colspan="1">24 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg BID, diclofenac SR
75 mg BID</td></tr><tr><td rowspan="1" colspan="1">I49-96-02-042</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">celecoxib 100 mg BID, diclofenac 50
mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-047</td><td rowspan="1" colspan="1">4 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 25 mg BID, celecoxib
100 mg BID, celecoxib
400 mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-054</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 50 mg BID,
celecoxib 100 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-060</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 100 mg BID,
celecoxib 200 mg QD</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-062</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg, naproxen 500 mg
BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-071</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg BID, diclofenac 75
mg BID, Ibuprofen 800 mg TID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-087</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 100 mg BID,
celecoxib 200 mg QD</td></tr><tr><td rowspan="1" colspan="1">I49-96-02-096</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 100 mg BID, celecoxib 200
mg BID, diclofenac 50 mg BID, naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-035/102
(CLASS trial)</td><td rowspan="1" colspan="1">Event-driven: median 6-9 months</td><td rowspan="1" colspan="1">celecoxib 400 mg BID, ibuprofen 800
mg TID, diclofenac 75 BID</td></tr><tr><td rowspan="1" colspan="1">I49-96-02-105</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 100 mg BID, diclofenac 50
mg BID</td></tr><tr><td rowspan="1" colspan="1">I49-96-02-106</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 100 mg BID, diclofenac 50
mg BID</td></tr><tr><td rowspan="1" colspan="1">I49-96-02-107</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 100 mg BID, diclofenac 50
mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-118</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 100 mg BID,
diclofenac 50 mg TID</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-149</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg QD, rofecoxib 25 mg
QD</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-152</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg QD, rofecoxib 25 mg
QD</td></tr><tr><td rowspan="1" colspan="1">N49-96-02-181</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg QD, rofecoxib 25 mg
QD</td></tr><tr><td rowspan="1" colspan="1">J49-01-02-216</td><td rowspan="1" colspan="1">4 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 100 mg BID,
loxoprofen 60 mg TID</td></tr><tr><td rowspan="1" colspan="1">635-IFL-0508-002</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg QD, rofecoxib 25 mg
QD, naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">635-IFL-0508-003</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD,
rofecoxib 25 mg QD</td></tr><tr><td rowspan="1" colspan="1">A3191006</td><td rowspan="1" colspan="1">52 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg QD, diclofenac 50
mg BID</td></tr><tr><td rowspan="1" colspan="1">A3191025</td><td rowspan="1" colspan="1">1 yr<xref ref-type="table-fn" rid="T1F2">a</xref></td><td rowspan="1" colspan="1">celecoxib 200 mg QD, diclofenac 50
mg BID</td></tr><tr><td rowspan="1" colspan="1">A3191051</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD,
naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">A3191052</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD,
naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">A3191053</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD,
naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">A3191062</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD,
ibuprofen 800 mg TID</td></tr><tr><td rowspan="1" colspan="1">A3191063</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD,
ibuprofen 800 mg TID</td></tr><tr><td rowspan="1" colspan="1">A3191069</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD</td></tr><tr><td rowspan="1" colspan="1">A3191082</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD</td></tr><tr><td rowspan="1" colspan="1">A3191152</td><td rowspan="1" colspan="1">6 Mths</td><td rowspan="1" colspan="1">celecoxib 200 mg QD, naproxen 500 mg
BID</td></tr><tr><td rowspan="1" colspan="1">COXA-0508-261</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg QD, diclofenac 50
mg TID</td></tr><tr><td colspan="3" rowspan="1"><bold>Ankylosing Spondylitis</bold></td></tr><tr><td rowspan="1" colspan="1">F49-98-02-137</td><td rowspan="1" colspan="1">6 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 100 mg BID,
ketoprofen 100 mg BID</td></tr><tr><td rowspan="1" colspan="1">N49-01-02-193</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD,
celecoxib 400 mg QD, naproxen 500 mg BID</td></tr><tr><td rowspan="1" colspan="1">COXA-0503-243</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg QD, celecoxib 200
mg BID, diclofenac 75 mg SR BID</td></tr><tr><td rowspan="1" colspan="1">COXA-0503-247</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg QD, celecoxib 400
mg QD, diclofenac 75 mg TID</td></tr><tr><td colspan="3" rowspan="1"><bold>Chronic Low Back Pain</bold></td></tr><tr><td rowspan="1" colspan="1">J49-01-02-217</td><td rowspan="1" colspan="1">4 Wks</td><td rowspan="1" colspan="1">celecoxib 100 mg BID, loxoprofen 60
mg TID</td></tr><tr><td rowspan="1" colspan="1">COXA-0508-244</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD</td></tr><tr><td rowspan="1" colspan="1">COXA-0508-245</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD</td></tr><tr><td rowspan="1" colspan="1">COXA-0508-269</td><td rowspan="1" colspan="1">12 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg QD,
celecoxib 200 mg BID</td></tr><tr><td rowspan="1" colspan="1">A3191174</td><td rowspan="1" colspan="1">4 Wks</td><td rowspan="1" colspan="1">celecoxib 200 mg BID, loxoprofen 60
mg TID</td></tr><tr><td colspan="3" rowspan="1"><bold>Alzheimer Disease</bold></td></tr><tr><td rowspan="1" colspan="1">IQ5-97-02-001</td><td rowspan="1" colspan="1">52 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg BID</td></tr><tr><td rowspan="1" colspan="1">EQ5-98-02-002</td><td rowspan="1" colspan="1">3 yr<xref ref-type="table-fn" rid="T1F2">a</xref></td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg BID</td></tr><tr><td rowspan="1" colspan="1">NQ5-98-02-005</td><td rowspan="1" colspan="1">4 Wks</td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg BID</td></tr><tr><td colspan="3" rowspan="1"><bold>Spontaneous Colorectal
Adenomatous Polyps </bold></td></tr><tr><td rowspan="1" colspan="1">NQ4-00-02-011</td><td rowspan="1" colspan="1">12 Wks<xref ref-type="table-fn" rid="T1F2">a</xref></td><td rowspan="1" colspan="1">placebo, celecoxib 100 mg BID,
celecoxib 200 mg BID, celecoxib 400 mg BID</td></tr><tr><td rowspan="1" colspan="1">EQ4-00-02-018</td><td rowspan="1" colspan="1">3 y<xref ref-type="table-fn" rid="T1F2">a</xref></td><td rowspan="1" colspan="1">placebo, celecoxib 400 mg QD</td></tr><tr><td rowspan="1" colspan="1">IQ4-99-02-005</td><td rowspan="1" colspan="1">3y<xref ref-type="table-fn" rid="T1F2">a</xref></td><td rowspan="1" colspan="1">placebo, celecoxib 200 mg BID,
celecoxib 400 mg BID</td></tr></tbody></table><table-wrap-foot><fn id="T1F1"><p>For this analysis, blood loss was predefined as a decrease in hemoglobin &#x02265;2 g/dL and/or hematocrit &#x02265;10% from baseline.</p><p>QD: once daily; BID: twice daily; TID: three times daily.</p></fn><fn id="T1F2"><label>a</label><p>Treatment with study medication was suspended or terminated early.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2.</label><caption><p>Baseline Demographics and Characteristics of
Patients Included in the Pooled Analysis</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th style="background-color:#D9D9D9;" rowspan="1" colspan="1"/><th style="background-color:#D9D9D9;" rowspan="1" colspan="1">Patients with Blood Loss (n=932)</th><th style="background-color:#D9D9D9;" rowspan="1" colspan="1">Patients without Blood Loss (n=50,116)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1"><bold>
Age, y</bold></td></tr><tr><td rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td rowspan="1" colspan="1">Median</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">61</td></tr><tr><td rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">21-91</td><td align="center" rowspan="1" colspan="1">17-96</td></tr><tr><td colspan="3" rowspan="1"><bold>
Race, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">White</td><td align="center" rowspan="1" colspan="1">746 (80)</td><td align="center" rowspan="1" colspan="1">38,166 (76)</td></tr><tr><td rowspan="1" colspan="1">Black</td><td align="center" rowspan="1" colspan="1">54 (5.8)</td><td align="center" rowspan="1" colspan="1">3218 (6.4)</td></tr><tr><td rowspan="1" colspan="1">Asian</td><td align="center" rowspan="1" colspan="1">102 (11)</td><td align="center" rowspan="1" colspan="1">5518 (11)</td></tr><tr><td rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">29 (3)</td><td align="center" rowspan="1" colspan="1">2970 (66)</td></tr><tr><td rowspan="1" colspan="1">Missing</td><td align="center" rowspan="1" colspan="1">1 (0.1)</td><td align="center" rowspan="1" colspan="1">244 (0.5)</td></tr><tr><td colspan="3" rowspan="1"><bold>
Sex, n (%)</bold></td></tr><tr><td rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">547 (59)</td><td align="center" rowspan="1" colspan="1">32,861 (66)</td></tr><tr><td rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">385 (41)</td><td align="center" rowspan="1" colspan="1">17,255 (34)</td></tr><tr><td colspan="3" rowspan="1"><bold>
Weight, kg</bold></td></tr><tr><td rowspan="1" colspan="1">Female, n (%)</td><td align="center" rowspan="1" colspan="1">544 (58)</td><td align="center" rowspan="1" colspan="1">32,778 (65)</td></tr><tr><td rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">76</td></tr><tr><td rowspan="1" colspan="1">Median</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">73</td></tr><tr><td rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">36-163</td><td align="center" rowspan="1" colspan="1">32-250</td></tr><tr><td colspan="3" rowspan="1"><bold>
Weight, kg</bold></td></tr><tr><td rowspan="1" colspan="1">Male, n (%)</td><td align="center" rowspan="1" colspan="1">383 (41)</td><td align="center" rowspan="1" colspan="1">17,225 (34)</td></tr><tr><td rowspan="1" colspan="1">Mean</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">88</td></tr><tr><td rowspan="1" colspan="1">Median</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">85</td></tr><tr><td rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">48-158</td><td align="center" rowspan="1" colspan="1">35-232</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float"><label>Table 3.</label><caption><p>Adverse Events (AEs) in Patients with Clinically
Significant Anemia/Blood Loss<xref ref-type="table-fn" rid="T3F1">a</xref> Versus those
Without (Threshold &#x02265;0.5%)</p></caption><table frame="border" rules="all" width="100%"><tr><th style="background-color:#D9D9D9;" rowspan="1" colspan="1">AEs, n (%)<xref ref-type="table-fn" rid="T3F2">b</xref></th><th style="background-color:#D9D9D9;" rowspan="1" colspan="1">Patients with Blood Loss (n=932)</th><th style="background-color:#D9D9D9;" rowspan="1" colspan="1">Patients without Blood Loss (n=50,116)</th></tr><tr><td rowspan="1" colspan="1"><bold>
Any AE</bold></td><td align="center" rowspan="1" colspan="1">612 (66)</td><td align="center" rowspan="1" colspan="1">29,222 (58)</td></tr><tr><td colspan="3" rowspan="1"><bold>
GI-Related AEs</bold></td></tr><tr><td rowspan="1" colspan="1">Gastric ulcer</td><td align="center" rowspan="1" colspan="1">14 (1.5)</td><td align="center" rowspan="1" colspan="1">101 (0.2)</td></tr><tr><td rowspan="1" colspan="1">GI hemorrhage</td><td align="center" rowspan="1" colspan="1">7 (0.8)</td><td align="center" rowspan="1" colspan="1">33 (&#x0003c; 0.1)</td></tr><tr><td rowspan="1" colspan="1">Esophageal ulcer</td><td align="center" rowspan="1" colspan="1">5 (0.5)</td><td align="center" rowspan="1" colspan="1">24 (&#x0003c; 0.1)</td></tr><tr><td rowspan="1" colspan="1">Melena</td><td align="center" rowspan="1" colspan="1">12 (1.3)</td><td align="center" rowspan="1" colspan="1">57 (0.1)</td></tr><tr><td colspan="3" rowspan="1"><bold>
Potential GI-Related AEs</bold></td></tr><tr><td rowspan="1" colspan="1">Anemia</td><td align="center" rowspan="1" colspan="1">82 (8.8)</td><td align="center" rowspan="1" colspan="1">317 (0.6)</td></tr><tr><td rowspan="1" colspan="1">Increase in blood creatinine</td><td align="center" rowspan="1" colspan="1">16 (1.7)</td><td align="center" rowspan="1" colspan="1">207 (0.4)</td></tr><tr><td rowspan="1" colspan="1">Decrease in hemoglobin</td><td align="center" rowspan="1" colspan="1">83 (8.9)</td><td align="center" rowspan="1" colspan="1">120 (0.2)</td></tr><tr><td rowspan="1" colspan="1">Decrease in hematocrit</td><td align="center" rowspan="1" colspan="1">97 (10.4)</td><td align="center" rowspan="1" colspan="1">228 (0.5)</td></tr><tr><td rowspan="1" colspan="1">Decrease in red blood cell count</td><td align="center" rowspan="1" colspan="1">7 (0.8)</td><td align="center" rowspan="1" colspan="1">23 (&#x0003c; 0.1)</td></tr><tr><td rowspan="1" colspan="1">Hematochezia</td><td align="center" rowspan="1" colspan="1">9 (1.0)</td><td align="center" rowspan="1" colspan="1">126 (0.3)</td></tr><tr><td colspan="3" rowspan="1"><bold>
Non-GI-Related AEs</bold></td></tr><tr><td rowspan="1" colspan="1">Coronary artery disease</td><td align="center" rowspan="1" colspan="1">11 (1.2)</td><td align="center" rowspan="1" colspan="1">144 (0.3)</td></tr><tr><td rowspan="1" colspan="1">Myocardial infarction</td><td align="center" rowspan="1" colspan="1">6 (0.6)</td><td align="center" rowspan="1" colspan="1">99 (0.2)</td></tr><tr><td rowspan="1" colspan="1">Pneumonia</td><td align="center" rowspan="1" colspan="1">16 (1.7)</td><td align="center" rowspan="1" colspan="1">202 (0.4)</td></tr></table><table-wrap-foot><fn id="T3F1"><label>a</label><p>Markedly higher, i.e. threefold difference between treatment groups in the incidence of AEs.</p></fn><fn id="T3F2"><label>b</label><p>Preferred terms based on MedDRA 11.0.</p></fn></table-wrap-foot></table-wrap></floats-group></article>